175 related articles for article (PubMed ID: 17726035)
21. Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab.
Mpofu S; Estrach C; Curtis J; Moots RJ
Rheumatology (Oxford); 2003 Sep; 42(9):1117-8. PubMed ID: 12923271
[No Abstract] [Full Text] [Related]
22. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?
Della Rossa A; Tavoni A; Merlini G; Baldini C; Sebastiani M; Lombardi M; Neglia D; Bombardieri S
Rheumatology (Oxford); 2005 Aug; 44(8):1074-5. PubMed ID: 15840604
[No Abstract] [Full Text] [Related]
23. A challenging case of Kikuchi-Fujimoto disease with systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis in a young man.
Pradhan S; Sirka CS; Dash G; Sahu K; Rout AN
Indian J Dermatol Venereol Leprol; 2021; 87(1):78-82. PubMed ID: 33580926
[No Abstract] [Full Text] [Related]
24. Hemophagocytic syndrome in a pregnant patient with systemic lupus erythematosus, complicated with preeclampsia and cerebral hemorrhage.
Pérard L; Costedoat-Chalumeau N; Limal N; Hot A; Cohen J; Vauthier-Brouzes D; Nieszkowska A; Belmatoug N; Piette JC
Ann Hematol; 2007 Jul; 86(7):541-4. PubMed ID: 17340134
[No Abstract] [Full Text] [Related]
25. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus.
Hayat SJ; Uppal SS
Mod Rheumatol; 2007; 17(2):174-7. PubMed ID: 17437178
[TBL] [Abstract][Full Text] [Related]
26. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
27. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease.
Christopher-Stine L; Wigley F
J Rheumatol; 2003 Dec; 30(12):2725-7. PubMed ID: 14719225
[No Abstract] [Full Text] [Related]
28. Anti-TNF-induced lupus.
Williams EL; Gadola S; Edwards CJ
Rheumatology (Oxford); 2009 Jul; 48(7):716-20. PubMed ID: 19416947
[TBL] [Abstract][Full Text] [Related]
29. Induction of systemic lupus erythematosus with tumor necrosis factor blockers.
Soforo E; Baumgartner M; Francis L; Allam F; Phillips PE; Perl A
J Rheumatol; 2010 Jan; 37(1):204-5. PubMed ID: 20040644
[No Abstract] [Full Text] [Related]
30. Infliximab infusions for persistent back pain in two patients with Schmorl's nodes.
Sakellariou GT; Chatzigiannis I; Tsitouridis I
Rheumatology (Oxford); 2005 Dec; 44(12):1588-90. PubMed ID: 16234274
[No Abstract] [Full Text] [Related]
31. [Up-date on the use of infliximab in dermatology. Introduction].
Sánchez-Carazo J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
[No Abstract] [Full Text] [Related]
32. Urinary beta2-microglobulin as a sensitive marker for haemophagocytic syndrome associated with collagen vascular diseases.
Onishi S; Ikenoya K; Matsumoto K; Kamata Y; Nagashima T; Kamimura T; Iwamoto M; Minota S
Rheumatology (Oxford); 2008 Nov; 47(11):1730-2. PubMed ID: 18784123
[No Abstract] [Full Text] [Related]
33. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
[TBL] [Abstract][Full Text] [Related]
34. Infliximab efficiency and failure.
Rozin AP
Ann Rheum Dis; 2004 Jun; 63(6):751-2; author reply 752. PubMed ID: 15140791
[No Abstract] [Full Text] [Related]
35. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
36. [The management of systemic lupus erythematosus with biological therapies].
Malaise O; von Frenckell C; André B; Malaise MG
Rev Med Suisse; 2013 Aug; 9(395):1507-11. PubMed ID: 24024419
[TBL] [Abstract][Full Text] [Related]
37. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
[No Abstract] [Full Text] [Related]
40. Hemophagocytic syndrome presenting with a facial erythema in a patient with systemic lupus erythematosus.
Sakai H; Otsubo S; Miura T; Iizuka H
J Am Acad Dermatol; 2007 Nov; 57(5 Suppl):S111-4. PubMed ID: 17938019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
